Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

• Regenxbio (RGNX), 315% surge in interest

Pipeline and key clinical candidates for these companies:

Regenxbio is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8 and AAV9. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a “5x’25” strategy to progress five AAV Therapeutics from its internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Recent news on these stocks:

October 10

Raymond James analyst Danielle Brill reinstated coverage of Regenxbio with an Outperform rating and $18 price target. Raymond James continues to see multiple growth-driving opportunities from Regenxbio’s pipeline, and thinks the stock is undervalued for RGX-314 in wet AMD and diabetic retinopathy and RGX-121 in Hunter Syndrome, the analyst tells investors in a research note. Following the broad approval of Sarepta’s (SRPT) DMD gene therapy in June, the firm sees a similar regulatory path for RGX-202, which represents an “interesting” commercial opportunity, even if the asset only captures about 15% of the population.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.